Pavel Klein
Dr. Pavel Klein is the Director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, MD. He is also Clinical Professor in the Department of Neurology at George Washington University in Washington, DC.
Dr. Klein completed his medical degree at the University of Cambridge in Cambridge, UK, neurology residency and epilepsy fellowship at the University of Virginia, and neuroendocrinology and sleep fellowships at Beth Israel Deaconess Medical Center/Harvard medical school. He was the director of the epilepsy program at Georgetown University until 2003 when he founded a private epilepsy center, the Mid-Atlantic Epilepsy and Sleep Center where he has been the director since then. He is board-certified in Psychiatry and Neurology, with added qualifications in Clinical Neurophysiology and in Epilepsy. In addition, he is a diplomate of the American Board of Sleep Medicine.
Dr. Klein’s clinical research includes novel treatments of epilepsy, prevention of epilepsy after traumatic brain injury, dietary treatments of epilepsy in adults, the effect of sex and stress hormones on epilepsy, and women with epilepsy. He has received research grants from the National Institutes of Health, the American Epilepsy Society and CURE/Department of Defense, as well as investigator-initiated study grants from several pharmaceutical companies. He has authored > 60 peer-reviewed articles. Dr. Klein is a Fellow of the American Academy of Neurology, Fellow of the American Epilepsy Society and member of the American Academy of Sleep Medicine. He is a member of the Executive Committee of the Epilepsy Consortium. He is a co-founder and CEO of a biotech start up, PrevEp LLC, which is developing treatments to prevent epilepsy after acquired CNS injury.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent Contractor (including contracted research)Ineligible company:aquestiveTopic:drug development/marketingDate added:01/06/2022Date updated:01/06/2022Relationship end date:01/06/2022
-
Attribution:SelfType of financial relationship:Independent Contractor (including contracted research)Ineligible company:EisaiTopic:drug development/marketingDate added:01/06/2022Date updated:01/06/2022Relationship end date:01/06/2022
-
Attribution:SelfType of financial relationship:Independent Contractor (including contracted research)Ineligible company:neurelisTopic:Drug development/marketingDate added:01/06/2022Date updated:01/06/2022Relationship end date:01/06/2022
-
Attribution:SelfType of financial relationship:Independent Contractor (including contracted research)Ineligible company:UCB PharmaTopic:Drug development /marketingDate added:01/06/2022Date updated:01/06/2022Relationship end date:01/06/2022
-
Attribution:SelfType of financial relationship:Independent Contractor (including contracted research)Ineligible company:SKL scienceTopic:Drug development/marketingDate added:01/06/2022Date updated:01/06/2022Relationship end date:01/06/2022
-
Attribution:SelfType of financial relationship:Independent Contractor (including contracted research)Ineligible company:SunovionTopic:speakerDate added:01/06/2022Date updated:01/06/2022Relationship end date:01/06/2022
-
Attribution:SelfType of financial relationship:Independent Contractor (including contracted research)Ineligible company:ArvelleTopic:drug developkment/marketingDate added:01/06/2022Date updated:01/06/2022Relationship end date:01/06/2022
-
Attribution:SelfType of financial relationship:Independent Contractor (including contracted research)Ineligible company:lundbeckTopic:drug developmentDate added:01/06/2022Date updated:01/06/2022Relationship end date:01/06/2022
-
Attribution:SelfType of financial relationship:Independent Contractor (including contracted research)Ineligible company:XenonTopic:drug developmentDate added:01/06/2022Date updated:01/06/2022Relationship end date:01/06/2022
-
Attribution:SelfType of financial relationship:Independent Contractor (including contracted research)Ineligible company:CereveleTopic:Drug developmentDate added:01/06/2022Date updated:01/06/2022Relationship end date:01/06/2022